WednesdaySep 22, 2021 9:15 am

Flora Growth Corp. (NASDAQ: FLGC) Makes Early Leap into Expected Opening of Cannabis Trade in Panama

Flora Growth Corp., a cannabis company with low-cost cultivation and global distribution, recently reached a non-binding LOI with Panamanian importer and distributor Robust Farms Inc. to supply product from its portfolio   Panama is a country on the verge of opening to medical marijuana sales and the first in Central America to open a regulated market following legislation approved without a dissenting vote by the National Assembly Flora Growth maintains a large licensed outdoor operation in Colombia, from which it cultivates cannabis that will be used in a variety of branded products  Flora Growth has been increasing its international outlets, including…

Continue Reading

FridaySep 17, 2021 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities

InMed Pharmaceuticals recently announced it has entered a definitive agreement to acquire 100% of BayMedica Inc. BayMedica is a private company that specializes in the manufacture and commercialization of rare cannabinoids Upon closing, the transaction will make InMed a global leader in the manufacturing of rare cannabinoids in addition to transforming it into a revenue-generating company Acquisition provides InMed with the complete flexibility across multiple manufacturing approaches On September 13, InMed Pharmaceuticals (NASDAQ: INM), a company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced it has signed a definitive agreement to acquire 100% of BayMedica…

Continue Reading

FridaySep 17, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Draws Closer to NDA Filing for DehydraTECH CBD

Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant” Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop in systolic pressure These results bring Lexaria closer to NDA filing with the FDA, making it a pioneer in CBD hypertension treatment  Lexaria Bioscience (NASDAQ: LEXX) just released the most recent results from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s…

Continue Reading

WednesdaySep 15, 2021 2:36 pm

Flora Growth Corp. (NASDAQ: FLGC) Receives its 2021 Commercial Export Quota Allocation from Colombian Government; Partners to Optimize Its Supply Chain By Implementing Global Cannabis Product Validation and Authentication Platform

Flora also recently announced it had received its 2021 commercial export quota allocation of 7,900 kilograms to cultivate, process, and distribute high-THC cannabis Flora Growth also announced it has entered into an agreement with Applied DNA Sciences, Inc. and TruTrace Technologies, Inc.  FLGC will deploy the two companies’ integrated technology as part of its global cannabis product validation and authentication platform The integrated technology will tag, test, and track Flora’s cannabis and cannabis derivative products during transit across an international supply chain, providing enhanced transparency, traceability, and trust As an internationally focused company, Flora Growth (NASDAQ: FLGC) has always strived…

Continue Reading

WednesdaySep 15, 2021 12:44 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology

Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s more ambitious goals There have been two successful human hypertension trials done with the combination DehydraTECH-CBD therapy in 2021, following an original human clinical study in 2018, and many animal studies Lexaria is making a strong case to support the efficacy of the technology for…

Continue Reading

MondaySep 13, 2021 3:02 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials

Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients The initial results of the first human clinical study showed the DehydraTECH-CBD compound was well tolerated by patients without troubling side effects and that the compound outperformed generic CBD controls Just-released initial (partial) results regarding the compound’s second human clinical trial show that a three-dose regimen…

Continue Reading

MondaySep 13, 2021 12:32 pm

Flora Growth Corp. (NASDAQ: FLGC) Expands Across International Borders into Europe and Asia

Flora Growth business divisions include pharmaceuticals, cosmetics, hemp textiles, and food & beverage sectors Flora Lab now has three GMP certifications – one each for cosmetics, phytotherapeutic products, and dietary supplements Flora Growth operates internationally but has its cultivation and processing operations based in Colombia – with one of the largest outdoor cultivation facilities in the world, aiming to produce medical-grade cannabis flower and derivative products at below-market pricing Proposed acquisitions of Vessel Brand and Koch & Gsell, as well as investment into Hoshi International, will help expand the business across international borders and into the US, Europe, and Asia…

Continue Reading

FridaySep 10, 2021 9:15 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Marks Impressive Performance for Q2 2021

$58.5 million in Adjusted Sales for first six months of 2021 The company also reported repaying approximately $18 million of debt and restructuring over $20 million into a long-term debt Q2 also marked RWB’s acquisition of Acreage Florida, as well as an operational 45,000 SF greenhouse within the state, which it projects, will begin harvesting in Q4 2021 RWB’s CEO expressed his optimism about the company’s performance in the Q3 and the second half of the year, given the strides made and the momentum realized in Q2  On August 30, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) released…

Continue Reading

ThursdaySep 09, 2021 1:28 pm

Flora Growth Corp. (NASDAQ: FLGC) Inks €2M Investment in Hoshi As Part of its European Expansion Plan

Flora closed a €2 million investment in Hoshi International Inc., fulfilling the earlier-announced LOI back in June 2021 This move is set to capitalize on Hoshi’s strong European presence, its technical know-how along with its understanding of the European market Hoshi acknowledged the investment with the announcement that it would work together with Flora to bring to market finished product formats from Flora’s brand portfolio Flora referred to this investment as the first of many steps by the company to advance its plans to launch products across the world On August 24, 2021, Flora Growth (NASDAQ: FLGC) announced closing a…

Continue Reading

ThursdaySep 09, 2021 12:59 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference

Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream As…

Continue Reading

HempWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722